Anti-SARS-CoV-2 antibody among SARS-CoV-2 vaccinated vs post-infected blood donors in a tertiary hospital, Bangkok, Thailand

Author:

Permpikul ParichartORCID,Tongyoo Surat,Chaimayo ChutikarnORCID,Kanpai Prapan,Virat Jitmanee,Virat Sutasinee,Chuchaaim Jaratsri,Thongput Anchalee,Bhatnagar SonuORCID

Abstract

SARS-CoV-2 virus infection has imposed a significant healthcare burden globally. To contain its spread and decrease infection-related mortality, several vaccines have been deployed worldwide in the past 3 years. We conducted a cross-sectional seroprevalence study to assess the immune response against the virus among blood donors at a tertiary care hospital, Bangkok, Thailand. From December 2021 to March 2022, total of 1,520 participants were enrolled, and their past history of SARS-CoV-2 infection and vaccination was recorded. Two serology test, namely, quantitative IgG spike protein (IgGSP) and qualitative IgG nucleocapsid antibody (IgGNC) were performed. The median age of study participants was 40 years (IQR 30–48) and 833 (54.8%) were men. Vaccine uptake was reported in 1,500 donors (98.7%) and 84 (5.5%) reported the past infection history. IgGNC was detected in 46/84 donors with the past infection history (54.8%) and in 36 out of the rest 1,436 (2.5%) with no past history. IgGSP positivity was observed in 1484 donors (97.6%). When compared to unvaccinated donors (n = 20), IgGSP level was higher in the donors who had received one vaccine dose (p< 0.001) and these antibody levels increased significantly among those with 3rd and 4th vaccine doses. Factors associated with low IgGSP (lowest quartile) by multivariate analysis included: no past infection history, homologous vaccination, < 3 vaccine doses, and > 90 days duration since last vaccination. In conclusion, vaccine uptake among our study donors was high (98.7%) and IgGSP antibody was observed in nearly all the vaccinated donors (97.6%). Previous SARS-CoV-2 infection, use of heterologous vaccination, vaccines ≥ 3 doses, and duration of the last vaccination >90 days affected IgGSP levels. Use of serological assays were found beneficial in the evaluation and differentiation of immune response to vaccination, and natural infection including the identification of previous asymptomatic infections.

Funder

Abbott Laboratories Pte Ltd, SIngapore

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference28 articles.

1. World Health Organization. COVID-19 dashboard: World Health Organization,; 2023 [updated March 28; cited 2023 March 28]. https://covid19.who.int/.

2. World Health Organization. Thailand: WHO Coronavirus Disease (COVID-19) Dashboard 2023 [updated March 29,2023; cited 2023 March 29]. https://covid19.who.int/region/searo/country/th.

3. Review of COVID-19 vaccine subtypes, efficacy and geographical distributions;AI Francis;Postgraduate Medical Journal,2022

4. Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects;Z Zhang;Frontiers in Immunology,2022

5. Our World in Data. Coronavirus (COVID-19) Vaccinations—Statistics and Research 2023 [updated April 4 cited 2023 April 4]. https://ourworldindata.org/covid-vaccinations.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3